{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-065634","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.135133+00:00","generated_at":"2026-05-24T04:14:26.562375+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"confidence":"high","headline":"Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026","bullets":["14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.","One durable CR in Merkel Cell Carcinoma (42+ weeks) and two PRs (MCC and MSI-H CRC, 12+ and 36+ weeks).","All patients with tumor shrinkage remain on study, suggesting potential for deepening responses.","Solnerstotug well tolerated: no DLTs; mild CRS in 4/60 patients (Grade 1 only).","Phase 2 initiation expected Q1 2026, subject to sufficient capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-065634","json":"https://secwatch.observer/filing/0001193125-25-065634.json","markdown":"https://secwatch.observer/filing/0001193125-25-065634.md","text":"https://secwatch.observer/filing/0001193125-25-065634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/0001193125-25-065634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/d831325d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:14:26.562375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}